• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心力衰竭所致慢性肺动脉高压的β3-肾上腺素能激动剂治疗试验设计

Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.

作者信息

Garcia-Lunar Ines, Blanco Isabel, Fernández-Friera Leticia, Prat-Gonzàlez Susanna, Jordà Paloma, Sánchez Javier, Pereda Daniel, Pujadas Sandra, Rivas Mercedes, Solé-Gonzalez Eduard, Vázquez Jorge, Blázquez Zorba, García-Picart Juan, Caravaca Pedro, Escalera Noemí, Garcia-Pavia Pablo, Delgado Juan, Segovia-Cubero Javier, Fuster Valentín, Roig Eulalia, Barberá Joan Albert, Ibanez Borja, García-Álvarez Ana

机构信息

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

出版信息

JACC Basic Transl Sci. 2020 Mar 11;5(4):317-327. doi: 10.1016/j.jacbts.2020.01.009. eCollection 2020 Apr.

DOI:10.1016/j.jacbts.2020.01.009
PMID:32368692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7188870/
Abstract

Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539).

摘要

毛细血管前和毛细血管后合并性高血压（CpcPH）是心力衰竭（HF）相对常见的并发症，预后较差。目前，尚无针对该病症的获批特效疗法。最近，在慢性肺动脉高压（PH）的大型动物转化模型中，使用β-3肾上腺素能受体（β3AR）激动剂治疗能够改善肺血流动力学和右心室（RV）功能。作者介绍了一项II期随机临床试验的设计，该试验旨在测试米拉贝隆（一种临床可用的β3AR激动剂）对因HF导致CpcPH患者的疗效。将评估β3AR治疗对肺血流动力学以及临床、生化和高级心脏成像参数的影响。（心力衰竭继发慢性肺动脉高压的β3激动剂治疗[SPHERE-HF]；NCT02775539）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/ac5749984fe8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/d8cb30f19adc/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/5fce796a747d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/ac5749984fe8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/d8cb30f19adc/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/5fce796a747d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8259/7188870/ac5749984fe8/gr2.jpg

相似文献

1
Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.心力衰竭所致慢性肺动脉高压的β3-肾上腺素能激动剂治疗试验设计
JACC Basic Transl Sci. 2020 Mar 11;5(4):317-327. doi: 10.1016/j.jacbts.2020.01.009. eCollection 2020 Apr.
2
β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.β3 肾上腺素能受体激动剂治疗心力衰竭相关慢性肺动脉高压（SPHERE-HF）：一项双盲、安慰剂对照、随机临床试验。
Eur J Heart Fail. 2023 Mar;25(3):373-385. doi: 10.1002/ejhf.2745. Epub 2022 Dec 4.
3
Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.左心疾病所致肺动脉高压的临床表型和结局：毛细血管前成分的作用。
PLoS One. 2018 Jun 19;13(6):e0199164. doi: 10.1371/journal.pone.0199164. eCollection 2018.
4
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial.β3 肾上腺素能受体刺激介导的环鸟苷酸依赖信号通路对晚期心力衰竭患者血流动力学的影响：一项随机、有创临床研究。
Circ Heart Fail. 2022 Jul;15(7):e009120. doi: 10.1161/CIRCHEARTFAILURE.121.009120. Epub 2022 Jun 27.
5
Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.在慢性肺动脉高压猪模型中，β-3肾上腺素能激动剂可降低肺血管阻力并改善右心室功能。
Basic Res Cardiol. 2016 Jul;111(4):49. doi: 10.1007/s00395-016-0567-0. Epub 2016 Jun 21.
6
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.左心疾病所致肺动脉高压的肺血管疾病：病理生理意义。
Eur Heart J. 2022 Sep 21;43(36):3417-3431. doi: 10.1093/eurheartj/ehac184.
7
Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study.远程血流动力学指导的心力衰竭管理对不同亚型肺动脉高压患者的影响：来自MEMS-HF研究的见解
Eur J Heart Fail. 2022 Dec;24(12):2320-2330. doi: 10.1002/ejhf.2656. Epub 2022 Nov 3.
8
Pulmonary hypertension due to left heart diseases.左心疾病所致肺动脉高压。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8. doi: 10.1016/j.jacc.2013.10.033.
9
Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component.运动时的肺动脉高压和通气：毛细血管前成分的作用。
J Heart Lung Transplant. 2017 Jul;36(7):754-762. doi: 10.1016/j.healun.2016.12.011. Epub 2016 Dec 23.
10
Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.主动脉瓣置换术治疗重度主动脉瓣狭窄患者肺动脉高压的血流动力学机制及其对长期预后的影响。
Eur J Heart Fail. 2019 Feb;21(2):172-181. doi: 10.1002/ejhf.1322. Epub 2018 Oct 17.

引用本文的文献

1
β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia-reperfusion injury.β3-肾上腺素能受体在心肌细胞中的过度表达使线粒体能够耐受缺血再灌注损伤。
Basic Res Cardiol. 2024 Oct;119(5):773-794. doi: 10.1007/s00395-024-01072-y. Epub 2024 Aug 12.
2
Characteristics of cardiopulmonary exercise testing in patients with combined post- and pre-capillary pulmonary hypertension due to left heart disease.左心疾病所致的后和前毛细血管性肺动脉高压合并患者心肺运动试验的特点。
PLoS One. 2023 May 22;18(5):e0286057. doi: 10.1371/journal.pone.0286057. eCollection 2023.
3
β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition.

本文引用的文献

1
Macitentan in pulmonary hypertension due to left ventricular dysfunction.马西替坦治疗左心功能障碍所致肺动脉高压。
Eur Respir J. 2018 Feb 7;51(2). doi: 10.1183/13993003.01886-2017. Print 2018 Feb.
2
Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.西地那非改善瓣膜病合并持续性肺动脉高压患者结局的多中心、双盲、随机临床试验。
Eur Heart J. 2018 Apr 14;39(15):1255-1264. doi: 10.1093/eurheartj/ehx700.
3
Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.
β3肾上腺素能受体激动剂米拉贝隆可预防右心室重构并促使动力相关蛋白1（Drp1）受到抑制。
Cardiovasc Diagn Ther. 2022 Dec;12(6):815-827. doi: 10.21037/cdt-22-274.
4
Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease.左心疾病相关肺动脉高压的治疗挑战和新兴治疗靶点。
J Am Heart Assoc. 2021 Jun;10(11):e020633. doi: 10.1161/JAHA.120.020633. Epub 2021 May 25.
5
Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭的右心表型。
Circ Heart Fail. 2021 Apr;14(4):e007840. doi: 10.1161/CIRCHEARTFAILURE.120.007840. Epub 2021 Apr 19.
6
The Beta3 Adrenergic Receptor in Healthy and Pathological Cardiovascular Tissues.健康与病态心血管组织中的β3 肾上腺素能受体。
Cells. 2020 Dec 2;9(12):2584. doi: 10.3390/cells9122584.
7
Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension.神经激素调节作为肺动脉高压的治疗靶点。
Cells. 2020 Nov 22;9(11):2521. doi: 10.3390/cells9112521.
8
Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.肺动脉高压的药理学：当前及新兴疗法概述
ACS Pharmacol Transl Sci. 2020 Jul 1;3(4):598-612. doi: 10.1021/acsptsci.0c00048. eCollection 2020 Aug 14.
主动脉瓣狭窄的超声心动图评估建议：欧洲心血管影像学会和美国超声心动图学会的重点更新
J Am Soc Echocardiogr. 2017 Apr;30(4):372-392. doi: 10.1016/j.echo.2017.02.009.
4
Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance.原发性瓣膜反流的非侵入性评估建议：美国超声心动图学会与心血管磁共振学会合作制定的报告
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371. doi: 10.1016/j.echo.2017.01.007. Epub 2017 Mar 14.
5
The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension.肺动脉高压中心脏右心室与其负荷的关系。
J Am Coll Cardiol. 2017 Jan 17;69(2):236-243. doi: 10.1016/j.jacc.2016.10.047.
6
The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.β3 肾上腺素能受体激动剂在慢性心力衰竭患者中首次人体随机试验：BEAT-HF 试验。
Eur J Heart Fail. 2017 Apr;19(4):566-575. doi: 10.1002/ejhf.714. Epub 2016 Dec 18.
7
Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension.对毛细血管后和毛细血管前合并性肺动脉高压的临床与生物学见解。
J Am Coll Cardiol. 2016 Dec 13;68(23):2525-2536. doi: 10.1016/j.jacc.2016.09.942.
8
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.超声心动图评估左心室舒张功能的建议：美国超声心动图学会和欧洲心血管影像学会的更新
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360. doi: 10.1093/ehjci/jew082. Epub 2016 Jul 15.
9
Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.在慢性肺动脉高压猪模型中，β-3肾上腺素能激动剂可降低肺血管阻力并改善右心室功能。
Basic Res Cardiol. 2016 Jul;111(4):49. doi: 10.1007/s00395-016-0567-0. Epub 2016 Jun 21.
10
Progress in Pulmonary Hypertension with Left Heart Failure. Beyond New Definitions and Acronyms.左心衰竭合并肺动脉高压的进展。超越新定义和首字母缩略词。
Am J Respir Crit Care Med. 2015 Nov 15;192(10):1152-4. doi: 10.1164/rccm.201507-1509ED.